EUCTR2004-001685-40-SK进行中（未招募）1 期
An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination with Intravenous Oxaliplatin (Q3W) (XELOX”) versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin with Intravenous Oxaliplatin (Q2W) (FOLFOX4”) as Treatment for Patients with Metastatic Colorectal Cancer who have Received Prior Treatment with CPT- 11 in Combination with 5-FU/LV as First Line Therapy.
Hoffmann-La Roche Inc0 个研究点目标入组 610 人开始时间: 2004年10月20日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 610
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •*) Male or female outpatients aged >= 18 years.
- •*) Be ambulatory and have a ECOG performance status of <=2.
- •*) Histologically confirmed adenocarcinoma of the colon or rectum with metastatic disease.
- •*) Patients whose disease has recurred or progressed during or within 6 months of completion of first line therapy with the combination of CPT-11 and 5-FU/LV, or patients stopping first line CPT-11/5-FU/LV combination therapy due to excessive toxicity within the first 8 weeks, as judged by the treating physician.
- •*) First line CPT-11 + 5-FU/LV may include the following:
- •- CPT11 + 5-FU/LV
- •- CPT11 + 5-FU (if infusional 5-FU)
- •- CPT11 + 5-FU/LV + concomitant (not sequential) targeted biological agent
- •*) Previous chemotherapy (i.e., CPT-11 and 5-FU/LV) must have been completed at least 3 weeks prior to randomization and any acute/delayed toxicity must have resolved.
- •*) Prior radiotherapy is permitted if it was not administered to target lesions selected for this study, unless progression of the selected target lesions within the radiation portal is documented, and provided it has been completed at least 4 weeks before randomization.
- •*) At least one unidimensionally measurable lesion with a diameter >20 mm using conventional CT or MRI scans or >10 mm using spiral CT scans (use of spiral CT must be documented in medical records.
- •*) Have a life expectancy of at least 3 months.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •*) Received more than one prior chemotherapeutic or other systemic anti-cancer treatment regimen in the metastatic setting.
- •*) Prior active or passive immunotherapy for metastatic disease, unless in combination with first line CPT-11 + 5-FU/LV.
- •*) Prior treatment with oxaliplatin.
- •*) Pregnant or lactating women.
- •*) Women of childbearing potential with either a positive or no pregnancy test at baseline. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential.
- •*) Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study.
- •*) History of another malignancy within the last five years except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix.
- •*) History or evidence upon physical examination of CNS disease (e.g., primary brain tumor, seizure not controlled with standard medical therapy, any brain metastases, or history of stroke).
- •*) History of psychiatric disability judged by the investigator to be clinically significant, precluding informed consent or interfering with compliance for oral drug intake.
- •*) Clinically significant (i.e. active) cardiovascular disease e.g. uncontrolled hypertension, unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, or grade II or greater peripheral vascular. In addition patients with myocardial infarction within 1 year prior to study treatment start will be excluded (see appendix 10).
- •*) Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, or inability to take oral medication.
- •*) Interstitial pneumonia or extensive symptomatic fibrosis of the lungs.
- •*) Known peripheral neuropathy ? NCI CTC grade 1. Absence of deep tendon reflexes (DTRs) as the sole neurologic abnormality does not render the patient ineligible.
- •*) Organ allografts requiring immunosuppressive therapy.
- •*) Serious uncontrolled intercurrent infections, or other serious uncontrolled concomitant disease.
- •*) Moderate or severe renal impairment [creatinine clearance equal to or below 50 mL/min (calculated according to Cockroft and Gault, Appendix 3)], or serum creatinine > 1.5 x upper limit of normal (ULN).
- •*) Any of the following laboratory values:
- •Absolute neutrophil count (ANC) < 1.5 x 109/L
- •Platelet count < 100 x 109/L
- •Total bilirubin > 1.5 x ULN
- •ALAT, ASAT > 2.5 x ULN, or > 5 x (ULN) in case of liver metastases
- •*) Alkaline phosphatase > 2.5 x ULN, or > 5 x ULN in case of liver metastases, or > 10 x ULN in case of bone metastases.
- •*) Prior unanticipated severe reaction to fluoropyrimidine therapy, or known dihydropyrimidine dehydrogenase (DPD) deficiency.
- •*) Known hypersensitivity to platinum compounds or any of the components of the study medications.
- •*) Major surgery within 4 weeks prior to study treatment start, or lack of complete recovery from the effects of major surgery.
研究者
相似试验
已完成
3 期
Research study to demonstrate that Intravenous iron isomaltoside is non-inferior to Oral iron sulphate in reducing iron deficiency in non-myeloid malignancies subjects associated with chemotherapy induced anaemia ,evaluated as ability to increase Haemoglobin (Hb).CTRI/2010/091/001478Pharmacosmos AS350
进行中（未招募）
不适用
A phase III, randomized, open-label study of intravenous iron isomaltoside 1000 (Monofer®) as mono therapy (without erythropoeisis stimulating agents) in comparison with oral iron sulfate in subjects with non-myeloid malignancies associated with Chemotherapy induced anaemia (CIA). - P-Monofer-CIA-01on-myeloid malignancies associated with Chemotherapy induced anaemia (CIA)MedDRA version: 12Level: LLTClassification code 10064014Term: Cancer anemiaEUCTR2009-016727-53-GBPharmacosmos A/S350
进行中（未招募）
不适用
A study to compare isomaltoside 1000 (Monofer®)(taken as injections) with iron sulfate taken as tablets in patients who have cancer and anemia caused by their treatment.Patients with non-myeloid malignancies associated with Chemotherapy Induced Anemia (CIA).MedDRA version: 14.1Level: LLTClassification code 10064014Term: Cancer anemiaSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 14.1Level: PTClassification code 10022972Term: Iron deficiency anaemiaSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2009-016727-53-SEPharmacosmos A/S350
进行中（未招募）
1 期
A phase III, randomized, open-label study of intravenous iron isomaltoside 1000 (Monofer®) as mono therapy (without erythropoeisis stimulating agents) in comparison with oral iron sulfate in subjects with non-myeloid malignancies associated with Chemotherapy induced anaemia (CIA). - P-Monofer-CIA-01non-myeloid malignancies associated with chemotherapy induced anaemia (CIA).MedDRA version: 12.1Level: LLTClassification code 10064014Term: Cancer anemiaEUCTR2009-016727-53-DKPharmacosmos A/S350
进行中（未招募）
1 期
A study to compare isomaltoside 1000 (Monofer®)(taken as injections) with iron sulfate taken as tablets in patients who have cancer and anemia caused by their treatment.EUCTR2009-016727-53-ESPharmacosmos A/S350